Zegalogue (dasiglucagon) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 0 Diseases   6 Trials   6 Trials   152 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zegalogue (dasiglucagon) / Novo Nordisk
2017-004546-15: A Trial to evaluate the Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Not yet recruiting
3
30
Europe
Dasiglucagon, ZP4207, Solution for injection in administration system
Zealand Pharma A/S, Zealand Pharma A/S
Children with congenital hyperinsulinism, Childrens with hereditary high level of insulin, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2018-000892-33: Treatment of hypoglycemia with dasiglucagon in children with T1DM

Not yet recruiting
3
40
Europe
Dasiglucagon, GlucaGen Hypokit, ZP4207, Solution for injection, Powder and solvent for solution for injection, GlucaGen Hypokit
Zealand Pharma A/S, Zealand Pharma A/S
Type 1 Diabetes mellitus, Type 1 Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2018-003834-34: A phase 3b, randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus

Not yet recruiting
3
88
Europe
Dasiglucagon A, Dasiglucagon B, ZP4207, Solution for injection
Zealand Pharma A/S, Zealand Pharma A/S
Type 1 Diabetes mellitus, Type 1 Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05378672: A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Recruiting
3
8
US
Dasiglucagon, Zegalogue, ZP4207
Zealand Pharma, Novo Nordisk A/S
Hypoglycemia, Type 1 Diabetes
09/24
09/24
NCT03941236 / 2017-004546-15: Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Active, not recruiting
3
44
Europe, US, RoW
dasiglucagon, ZP4207
Zealand Pharma, Zealand Pharma A/S
Congenital Hyperinsulinism
01/25
01/25
2019-001915-22: Hormone treatment of low blood sugar due to meal ingestion in individuals with a reduced stomach size Hormonbehandling af lavt blodsukker ved indtagelse af måltid hos individer med reduceret mavesækstørrelse

Not yet recruiting
2
10
Europe
Dasiglucagon (4 mg/mL), ZP4207, Injection
Center for Clinical Metabolic Research at Herlev-Gentofte Hospital, Zealand Pharma
Postprandial hyperinsulinemic hypoglycaemia, Low blood sugar due to meal ingestion in postoperative Roux-En-Y individuals., Body processes [G] - Metabolic Phenomena [G03]
 
 
2020-000551-12: Dasiglucagon for Prevention of Low Blood Glucose Levels in People with Type 1 Diabetes Dasiglucagon til forebyggelse af lavt blodsukker hos personer med type 1 diabetes

Not yet recruiting
2
20
Europe
Dasiglucagon, Solution for injection
Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Zealand Pharma A/S
Type 1 diabetes, Type 1 diabetes is a metabolic disease characterized by deficient insulin production., Diseases [C] - Hormonal diseases [C19]
 
 
2020-005745-16: Pen-Administered Dasiglucagon for Prevention and Treatment of Low Blood Glucose Levels in People with Type 1 Diabetes To-ugers afprøvning af glukagonpen til forebyggelse og behandling af lavt blodsukker hos personer med type 1 diabetes

Not yet recruiting
2
24
Europe
Dasiglucagon, Solution for injection in cartridge
Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Zealand Pharma A/S
Type 1 diabetes, Type 1 diabetes is a metabolic disease characterized by deficient insulinproduction., Diseases [C] - Hormonal diseases [C19]
 
 
2022-000427-20: a new kind of glucagon for the artificial pancreas een nieuw soort glucagon voor een kunstmatige alvleesklier

Not yet recruiting
2
12
Europe
Dasiglucagon, ZP4207, Solution for injection
Inreda Diabetic, Zealand Pharma
Type 1 Diabetes mellitus Type 1 Diabetes mellitus, Type 1 Diabetes mellitus Suikerziekte type 1, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04824872: Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Withdrawn
2
24
NA
Dasiglucagon, Placebo
Zealand Pharma
Hypoglycemia, Glucose Metabolism Disorders
02/23
02/23
STABLE-1, NCT05454709 / 2022-000427-20: A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System

Withdrawn
2
12
Europe
Dasiglucagon, GlucaGen
Inreda Diabetic B.V., Zealand Pharma
Diabetes Mellitus, Type 1
12/23
12/23
NCT04192019: Micro Glucagon During Exercise in Type 1 Diabetes

Withdrawn
1
20
NA
Micro-glucagon, Dasiglucagon, Mini-glucagon
Insel Gruppe AG, University Hospital Bern
Type 1 Diabetes, Hypoglycemia
04/24
06/24
NN9515-7675, NCT06588504: Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Recruiting
1
38
Japan
Dasiglucagon, Glucagon
Novo Nordisk A/S
Diabetes Mellitus, Type 1
06/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zegalogue (dasiglucagon) / Novo Nordisk
2017-004546-15: A Trial to evaluate the Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Not yet recruiting
3
30
Europe
Dasiglucagon, ZP4207, Solution for injection in administration system
Zealand Pharma A/S, Zealand Pharma A/S
Children with congenital hyperinsulinism, Childrens with hereditary high level of insulin, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2018-000892-33: Treatment of hypoglycemia with dasiglucagon in children with T1DM

Not yet recruiting
3
40
Europe
Dasiglucagon, GlucaGen Hypokit, ZP4207, Solution for injection, Powder and solvent for solution for injection, GlucaGen Hypokit
Zealand Pharma A/S, Zealand Pharma A/S
Type 1 Diabetes mellitus, Type 1 Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2018-003834-34: A phase 3b, randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus

Not yet recruiting
3
88
Europe
Dasiglucagon A, Dasiglucagon B, ZP4207, Solution for injection
Zealand Pharma A/S, Zealand Pharma A/S
Type 1 Diabetes mellitus, Type 1 Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05378672: A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Recruiting
3
8
US
Dasiglucagon, Zegalogue, ZP4207
Zealand Pharma, Novo Nordisk A/S
Hypoglycemia, Type 1 Diabetes
09/24
09/24
NCT03941236 / 2017-004546-15: Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Active, not recruiting
3
44
Europe, US, RoW
dasiglucagon, ZP4207
Zealand Pharma, Zealand Pharma A/S
Congenital Hyperinsulinism
01/25
01/25
2019-001915-22: Hormone treatment of low blood sugar due to meal ingestion in individuals with a reduced stomach size Hormonbehandling af lavt blodsukker ved indtagelse af måltid hos individer med reduceret mavesækstørrelse

Not yet recruiting
2
10
Europe
Dasiglucagon (4 mg/mL), ZP4207, Injection
Center for Clinical Metabolic Research at Herlev-Gentofte Hospital, Zealand Pharma
Postprandial hyperinsulinemic hypoglycaemia, Low blood sugar due to meal ingestion in postoperative Roux-En-Y individuals., Body processes [G] - Metabolic Phenomena [G03]
 
 
2020-000551-12: Dasiglucagon for Prevention of Low Blood Glucose Levels in People with Type 1 Diabetes Dasiglucagon til forebyggelse af lavt blodsukker hos personer med type 1 diabetes

Not yet recruiting
2
20
Europe
Dasiglucagon, Solution for injection
Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Zealand Pharma A/S
Type 1 diabetes, Type 1 diabetes is a metabolic disease characterized by deficient insulin production., Diseases [C] - Hormonal diseases [C19]
 
 
2020-005745-16: Pen-Administered Dasiglucagon for Prevention and Treatment of Low Blood Glucose Levels in People with Type 1 Diabetes To-ugers afprøvning af glukagonpen til forebyggelse og behandling af lavt blodsukker hos personer med type 1 diabetes

Not yet recruiting
2
24
Europe
Dasiglucagon, Solution for injection in cartridge
Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Zealand Pharma A/S
Type 1 diabetes, Type 1 diabetes is a metabolic disease characterized by deficient insulinproduction., Diseases [C] - Hormonal diseases [C19]
 
 
2022-000427-20: a new kind of glucagon for the artificial pancreas een nieuw soort glucagon voor een kunstmatige alvleesklier

Not yet recruiting
2
12
Europe
Dasiglucagon, ZP4207, Solution for injection
Inreda Diabetic, Zealand Pharma
Type 1 Diabetes mellitus Type 1 Diabetes mellitus, Type 1 Diabetes mellitus Suikerziekte type 1, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04824872: Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Withdrawn
2
24
NA
Dasiglucagon, Placebo
Zealand Pharma
Hypoglycemia, Glucose Metabolism Disorders
02/23
02/23
STABLE-1, NCT05454709 / 2022-000427-20: A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System

Withdrawn
2
12
Europe
Dasiglucagon, GlucaGen
Inreda Diabetic B.V., Zealand Pharma
Diabetes Mellitus, Type 1
12/23
12/23
NCT04192019: Micro Glucagon During Exercise in Type 1 Diabetes

Withdrawn
1
20
NA
Micro-glucagon, Dasiglucagon, Mini-glucagon
Insel Gruppe AG, University Hospital Bern
Type 1 Diabetes, Hypoglycemia
04/24
06/24
NN9515-7675, NCT06588504: Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Recruiting
1
38
Japan
Dasiglucagon, Glucagon
Novo Nordisk A/S
Diabetes Mellitus, Type 1
06/25
08/25

Download Options